{"public_id":"co_e9d05b14460da179550f4e933107d554","status":"active","merged_into_public_id":null,"resolved_public_id":"co_e9d05b14460da179550f4e933107d554","name":"fibrosis progression","description":"Advancement of liver fibrosis measured as a treatment outcome.","aliases":[],"types":["outcome"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":35926507,"title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","citation_count":1570,"url":"https://sah.borca.ai/papers/35926507"}],"claims":[{"public_id":"cl_e105139d57fd54d4c6ab9c9b3a26720f","text":"The 100 mg dose was associated with reduced progression of fibrosis, the highest rate of HBeAg seroconversion, the greatest suppression of HBV DNA, and the highest rate of sustained normalization of alanine aminotransferase levels.","corpus_id":35926507,"url":"https://sah.borca.ai/claims/cl_e105139d57fd54d4c6ab9c9b3a26720f"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_e9d05b14460da179550f4e933107d554","url":"https://sah.borca.ai/concepts/co_e9d05b14460da179550f4e933107d554"}